Dabrafenib and/or Trametinib Rollover Study
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is to provide access for patients who are receiving treatment with dabrafenib and/or trametinib in a Novartis-sponsored Oncology Global Development, Global Medical Affairs or a former GSK-sponsored study who have fulfilled the requirements for the primary objective, and who are judged by the investigator as benefiting from continued treatment in the parent study as judged by the Investigator at the completion of the parent study.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent aktualnie otrzymuje leczenie dabrafenibem i/lub trametinibem w badaniu firmy Novartis lub dawnej GSK
- •Badanie główne zostało ukończone i osiągnęło swoje cele
- •Według lekarza prowadzącego pacjent będzie miał korzyść z dalszego leczenia
✗ Disqualifies
- •Pacjent wcześniej przerwał stale leczenie w głównym badaniu
- •Leczenie tego schorzenia jest dostępne i refundowane w kraju pacjenta
- •Pacjent ma nieustalone skutki uboczne leczenia, z powodu których przerwano dawkowanie w głównym badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 100 Years
- Last updated (source)
- July 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (32)
Honor Health Research Institute
Scottsdale, United States
National Institute Of Health
Bethesda, United States
James Cancer Hospital and Solove Research Institute Ohio State
Columbus, United States
Mary Crowley Cancer Research
Dallas, United States
Novartis Investigative Site
Caba, Argentina
Novartis Investigative Site
Innsbruck, Austria
Novartis Investigative Site
Beijing, China
Novartis Investigative Site
Copenhagen, Denmark
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Nantes, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Villejuif, France
Novartis Investigative Site
Mannheim, Germany
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Essen, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Heidelberg, Germany
Novartis Investigative Site
Debrecen, Hungary
Novartis Investigative Site
Budapest, Hungary
Novartis Investigative Site
Kashiwa, Japan
Novartis Investigative Site
Chuo Ku, Japan
Novartis Investigative Site
Rotterdam, Netherlands
Novartis Investigative Site
Utrecht, Netherlands
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Valencia, Spain
Novartis Investigative Site
Songkhla, Thailand
Trial contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.